Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin alpha-11 (PCDHA11) is a neural cadherin-like cell adhesion protein and a member of the protocadherin alpha gene cluster, which contains 15 related genes organized similarly to immune receptor gene clusters[1][3][5][6]. The protein is an integral plasma membrane protein, predicted to function as a calcium-dependent cell adhesion molecule, and is thought to play a critical role in the establishment and maintenance of specific neuron-neuron connections in the brain, thereby contributing to neural circuit assembly[1][5][6]. Mutations or copy number variations in the PCDHA11 gene may be involved in neurodevelopmental disorders such as autism spectrum disorder[1]. The molecular mechanism is based on its extracellular cadherin domains mediating homophilic (isoform-specific) interactions, which are required for neuronal recognition and circuit assembly[6]. The intracellular domain can participate in signaling pathways, including Wnt, WAVE, and apoptotic pathways, relevant to brain development and potentially cancer biology[4]. No direct therapeutic drugs or clinical biomarkers are established for this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin alpha-11 (PCDHA11).